A new CMS proposed rule seeks to encourage the use of lower-cost biosimilars instead of reference biologics under Medicare Part D. The proposed rule would modify the definition of generic drugs—for the purposes of non–low-income-subsidy (LIS) catastrophic and LIS cost-sharing—to include biosimilar therapies.
A new CMS proposed rule seeks to encourage the use of lower-cost biosimilars instead of reference biologics under Medicare Part D. The proposed rule would modify the definition of generic drugs—for the purposes of non—low-income-subsidy (LIS) catastrophic and LIS cost-sharing—to include biosimilar therapies.
CMS reports that it has received numerous requests to redefine generic drugs, noting that advocates have expressed concerns that LIS Medicare enrollees are required to pay higher brand copayments for biosimilars, and that treating biosimilars as branded products for the purpose of LIS cost-sharing creates a disincentive for LIS enrollees (as well as non-LIS enrollees in the catastrophic portion of the benefit) to select lower-cost therapies.
The proposed rule would revise the definition of generic drug to include “follow-on biological products” for purposes of cost-sharing, which CMS predicts will incentivize enrollees to choose biosimilars and thereby reduce costs to the Part D program.
CMS emphasized that the rule would treat biosimilars as generics solely for cost-sharing purposes: “We want to avoid causing any confusion or misunderstanding that CMS treats follow-on biological products as generic drugs in all situations. We do not believe that would be appropriate because the same FDA requirements for generic drug approval (for example, therapeutic equivalence) do not apply to biosimilar biological products, currently the only available follow-on biological products,” according to the proposed rule. “Accordingly, CMS currently considers biosimilar biological products more like brand-name drugs for purposes of transition or midyear formulary changes because they are not interchangeable.”
Notably, the proposed rule does not include language to address reduced patient cost-sharing in Part D coverage gap (or the so-called “donut hole”), nor does it include language that would change the requirement for a biosimilar manufacturer to provide a 50% rebate for products while a patient is in the coverage gap.
CMS is also contemplating other changes to help reduce the price of drugs under Part D, including requiring a percentage of manufacturers’ rebates that have been negotiated for a drug covered under Part D to be included in the drug’s point-of-sale price. This change targets the rebates and discounts negotiated between manufacturers pharmacy benefit managers (PBMs) that are not being passed along to Medicare beneficiaries.
Currently, according to the proposed rule, “Part D sponsors are allowed, but generally not required, to apply rebates and other price concessions at the point of sale to lower the price upon which beneficiary cost-sharing is calculated. To date, sponsors have elected to include rebates and other price concessions in the negotiated price at the point-of-sale only very rarely.”
CMS will take comments on the proposed rule until January 16, 2018.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.